

# AACR Special Conference on Targeting RAS

March 5-8, 2023 | Philadelphia, PA


## DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Aguirre	Andrew	Riva Therapeutics, Revolution Medicines, Merck, Boehringer Ingelheim, Syros Therapeutics, Mirati Therapeutics, AstraZeneca, T-knife Therapeutics	IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Arthur	Ronald	No Relationships		Staff
Baliira	Rachael	No Relationships		Speaker
Barbacid	Mariano	No Relationships		Program Committee, Speaker
Bar-Sagi	Dafna	No Relationships		Program Committee, Speaker
Bear	Adham	Patent - Compositions and Methods for Targeting Mutant RAS	P	Speaker
Bernards	Rene	Heparegenix, Agendia, LixteBiotechnologyHoldings	GC, S, FO	Speaker
Bryant	Kirsten	Sky Foundation, SpringWorks Therapeutics, Verastem, Inc.	IC, GC, GC	Speaker
Burd	Christin	TruDiagnostic, Gilead Sciences, EMD Millipore Corporation, AbbVie, Luminex Corporation	G, S, IP, S, S	Program Committee, Speaker
Castel	Pau	Venthera, Inc.	IC	Speaker
Christensen	James	Mirati Therapeutics, Mirati Therapeutics, Mirati Therapeutics, Mirati Therapeutics	FO, SO, S, E	Speaker
Cichowski	Karen	Erasca, Inc	IC	Speaker
Der	Channing	Revolution Medicines, Mirati Therapeutics	GC, IC	Speaker
Downward	Julian	Bristol-Myers Squibb, AstraZeneca, Revolution Medicines, Jubilant Therapeutics, BridgeBio Pharma, Roche	GC, GC, GC, IC, IC, IC	Program Committee, Speaker
Ghazi	Phaedra	No Relationships		Speaker






# AACR Special Conference on Targeting RAS

March 5-8, 2023 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Kimmelman	Alec	Patent, Patent, Patent, Patent, Vescor, rafael therapeutics, oncorev	P, P, P, P, SO, SO, IC	Speaker
Leonard	M. Kathryn	No Relationships		Staff
Lito	Piro	Patent - treatment of KRAS or BRAF mutant cancers, Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim, Virtec Pharmaceuticals, Black Diamond Therapeutics, AmMax, OrbiMed, Repare Therapeutics, Boehringer Ingelheim, Revolution Medicines, Frontier Medicines	P, GC, GC, GC, GC, GC, O, O, O, O, T, O, O, SO	Speaker
Magits	Wout	No Relationships		Speaker
Malek	Shiva	Novartis, Genentech, Novartis, Novartis	E, E, S, SO	Speaker
McCormick	Frank	Amgen, Pellepharm, Frontier Medicines, Daiichi Sankyo Company, PMV, Leidos Biomedical Research, Ideaya Biosciences, Quanta Therapeutics, Exuma Biotech, Olema Pharmaceuticals, Boehringer Ingelheim, BridgeBio Pharma, PFIZER PHARMA GMBH, Kura Oncology Biotech	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC	Program Committee
Misale	Sandra	Boehringer Ingelheim, Daiichi Sankyo Company	GC, GC	Speaker
Morrison	Deborah	No Relationships		Program Committee
Pasca Di Magliano	Marina	No Relationships		Speaker
Perera	Rushika	Lime Therapeutics, Lime Therapeutics	SO, IC	Speaker
Post	Dean	No Relationships		Staff
Ratner	Nancy	No Relationships		Speaker
Rosen	Neal	Aadi Bioscience, AstraZeneca, AstraZeneca, BeiGene, BeiGene, Boehringer, Chugai Pharmaceuticals, Chugai Pharmaceuticals, eFFECTOR, eFFECTOR, Ikena Oncology, Ikena Oncology, Jubilant Therapeutics, Kura Oncology, MapKure, MapKure, Pfizer, Pfizer, Revolution Medicines, Ribon Therapeutics, Ribon Therapeutics, Verastem, Zai Laboratories, Zai Laboratories Lutris Pharma,	IC, IC, GC, IC, S, GC, IC, GC, GC, S, IC, SO, IC, S, IC, S, IC, GC, GC, IC, S, IC, IC, S, P	Speaker
Rusten	Tor	No Relationships		Speaker
Sharma	Alok	No Relationships		Speaker



# AACR Special Conference on Targeting RAS

March 5-8, 2023 | Philadelphia, PA

## DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Shokat	Kevan	Genentech, Merck, eFFECTOR, Biotheryx, Denali, Apertor, Janssen Biotech	IC, IC, S, IC, IC, SO, IC	Speaker
Simanshu	Dhirendra	No Relationships		Speaker
Smith	Kathryn	Arvinas Operations, Inc., Arvinas Operations, Inc., Arvinas Operations, Inc.	E, S, SO	Speaker
Spencer-Smith	Russell	No Relationships		Speaker
Sudhamsu	Jawahar	Genentech USA, Inc., Genentech USA, Inc.	E, SO	Speaker
Tartaglia	Marco	No Relationships		Program Committee, Speaker
Tuveson	David	Surface Oncology, Mestag Therapeutics, Leap Therapeutics, Sonata Therapeutics, Xilis, Surface Oncology, Xilis, Leap Therapeutics, Sonata Therapeutics, Mestag Therapeutics, Mestag Therapeutics, ONO Pharmaceutical	IC, IC, S, IC, SO, SO, IC, IC, SO, GC, S, GC	Program Committee, Speaker
Wood	Laura	Patent	P	Speaker
Zhang	X. Michelle	Ikena Oncology	E	Speaker

**All of the relevant financial relationships listed for these individuals have been mitigated.**